"The voice for cancer physicians and their patients in Massachusetts."

Updates for Bristol Myers Squibb's ISTODAX® for injection, for intravenous use

20 Oct 2021 3:00 PM | Katy Monaco (Administrator)

The CMS 2021 ASP Drug Pricing Files for the 4th quarter effective October 1, 2021 through December 31, 2021 reflects updates for ISTODAX® (romidepsin) for injection, for intravenous use.  The update includes the following changes which are effective October 1, 2021:

  • Discontinued HCPCS Code J9315 “Injection, romidepsin, 1mg” on September 30, 2021 and established J9319 “Injection, romidepsin, lyophilized, 0.1mg” on October 1, 2021.
  • Changed the HCPCS Code Dosage from 1mg to 0.1 mg.

Per CMS, this change in J-code needed to be made because: “A new HCPCS code for Romidepsin Injection, non-lyophilized liquid is needed because it is a single source drug approved under a unique NDC number, and it needs to be differentiated from the existing HCPCS code for a multi-sourced Romidepsin drug in lyophilized powder form."

Massachusetts Society of Clinical Oncologists ©2022

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  Fax: 781.464.4896  |  email: msco@mms.org

Powered by Wild Apricot Membership Software